1.
Haznedaroglu IC. MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML). Mediterr J Hematol Infect Dis [Internet]. 2013Dec.31 [cited 2020Mar.31];6(1):e2014009. Available from: http://www.mjhid.org/index.php/mjhid/article/view/2014.009